
    
      A Phase IIb, 96 week, randomized, partially double-blinded, multicenter, parallel group,
      repeat dose study to evaluate the safety, tolerability, pharmacokinetics and antiviral effect
      of GW873140 in combination with Combivir (lamivudine and zidovudine) upon selected
      immunological and virological markers of HIV-1 infection in antiretroviral therapy naive
      adults
    
  